|
Real-time Estimate
Cboe BZX
11:50:17 2026-11-04 EST
|
5-day change | 1st Jan Change | ||
| 22.53 USD | +2.60% |
|
-2.99% | +26.70% |
| 10-27 | Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading | MT |
| 10-26 | Zai Lab's Lung Cancer Drug Achieves Promising Response Rate in Phase 1b Trial; Shares up 4% | MT |
| Market Cap | 2.73B 2.44B 2.24B 2.03B 3.82B 258B 3.91B 26.71B 10.74B 136B 10.23B 10.01B 432B | P/E 2026 * |
-9.78x | P/E 2027 * | -10x |
|---|---|---|---|---|---|
| Enterprise Value | 2.22B 1.98B 1.82B 1.65B 3.1B 210B 3.18B 21.72B 8.74B 111B 8.32B 8.14B 351B | EV / Sales 2026 * |
5.14x | EV / Sales 2027 * | 4.16x |
| Free-Float |
94.05% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| ZLAB | Delayed | |
CBOE
| ZLAB | Real-time | |
|
Tradegate
| 1ZL | Real-time | |
|
Deutsche Boerse AG
| 1ZL | Delayed | |
|
Börse Stuttgart
| 1ZL | Delayed | |
|
Boerse Muenchen
| 1ZL | Real-time |
Last Transcript: Zai Lab Limited
| 1 day | +2.62% | ||
| 1 week | -2.99% | ||
| Current month | +1.27% | ||
| 1 month | -12.76% | ||
| 3 months | +20.88% | ||
| 6 months | +5.33% | ||
| Current year | +26.70% |
| 1 week | 21.42 |  | 23.4 |
| 1 month | 21.42 | | 26.92 |
| Current year | 15.96 | | 27.5 |
| 1 year | 15.96 | | 27.5 |
| 3 years | 13.48 | | 44.34 |
| 5 years | 13.48 | | 102.43 |
| 10 years | 13.48 | | 193.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ying Du
CEO | Chief Executive Officer | 61 | 2014-03-31 |
Ya jing Chen
DFI | Director of Finance/CFO | 58 | 2023-07-06 |
Rafael Amado
PSD | President | 62 | 2022-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Ying Du
CHM | Chairman | 61 | 2014-03-31 |
John Diekman
BRD | Director/Board Member | 83 | 2016-12-31 |
Peter Wirth
BRD | Director/Board Member | 75 | 2016-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/1/26 | Exercice | Chief Financial Officer | 2,155 | 0.0002% | ||
| 8/19/26 | Sell | Chief Financial Officer | -260 | 0.0000% | ||
| 8/14/26 | Exercice | Chief Financial Officer | 2,927 | 0.0003% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.60% | -2.99% | -13.67% | -19.98% | 2.73B | |
| +1.29% | +10.92% | +57.58% | +140.10% | 1,255B | |
| +2.26% | +0.37% | +45.58% | +79.32% | 641B | |
| +1.15% | +1.07% | +33.88% | +104.70% | 505B | |
| +1.25% | -0.73% | +49.96% | +66.94% | 381B | |
| +2.44% | +5.01% | +76.48% | +41.84% | 357B | |
| +2.10% | +3.90% | +32.30% | +59.38% | 303B | |
| +1.92% | +9.92% | +11.99% | +36.53% | 286B | |
| +3.67% | +5.17% | +60.16% | +74.17% | 249B | |
| +3.60% | +8.85% | +40.89% | +113.57% | 208B | |
| Average | +2.09% | +1.96% | +39.52% | +69.66% | 418.8B | |
| Weighted average by Cap. | +1.81% | +3.89% | +48.14% | +93.24% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 432M 386M 354M 322M 604M 40.9B 620M 4.23B 1.7B 21.59B 1.62B 1.59B 68.42B | 547M 489M 449M 408M 766M 51.84B 785M 5.36B 2.16B 27.36B 2.05B 2.01B 86.72B |
| Net income | -244M -218M -200M -182M -342M -23.12B -350M -2.39B -962M -12.2B -916M -897M -38.68B | -220M -196M -180M -164M -307M -20.8B -315M -2.15B -865M -10.98B -824M -807M -34.8B |
| Net Debt | -509M -455M -418M -379M -712M -48.21B -730M -4.99B -2.01B -25.45B -1.91B -1.87B -80.65B | -449M -401M -368M -334M -628M -42.49B -644M -4.39B -1.77B -22.43B -1.68B -1.65B -71.08B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-04 | US$22.35 | +1.78% | 301,670 |
| 26-11-03 | US$21.96 | +1.36% | 2,523,020 |
| 26-11-02 | US$21.67 | -1.84% | 473,887 |
| 26-10-30 | US$22.07 | -1.30% | 637,839 |
| 26-10-29 | US$22.36 | -2.95% | 648,511 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZLAB Stock
Select your edition
All financial news and data tailored to specific country editions
